Serotonin transporter occupancy with TCAs and SSRIs: A PET study in patients with major depressive disorder

International Journal of Neuropsychopharmacology

Volumn 15, Issue 8, 2012, Pages 1167-1172

  Lundberg, Johan ^a   Tiger, Mikael ^a   Landén, Mikael ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 HTT; depression; PET; SSRI; TCA

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; MIRTAZAPINE; N, N DIMETHYL 2(2 AMINO 4 METHYLPHENYLTHIO)BENZYLAMINE C 11; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; RECEPTOR OCCUPANCY; REMISSION; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZYLAMINES; CARBON RADIOISOTOPES; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84864563043     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001945     Document Type: Article

References (25)

1. Anderson IM (1998). SSRIs vs. tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression and Anxiety 7, 11-17.
2. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, et al. (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. Journal of Neuroscience 19, 10 494-10 501.
3. Bergström M, Boëthius J, Eriksson L, Greitz T, et al. (1981). Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. Journal of Computer Assisted Tomography 5, 136-141.
4. Carlsson A, Corrodi H, Fuxe K, Hökfelt T (1969a). Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4,a-dimethyl-meta-tyramine. European Journal of Pharmacology 5, 357-366.
5. Carlsson A, Corrodi H, Fuxe K, Hökfelt T (1969b). Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,a-dimethyl-meta-tyramine. European Journal of Pharmacology 5, 367-373.
6. Farde L, Nordström A-L, Wiesel F-A, Pauli S, et al. (1992). Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry 49, 538-544.
7. Ginovart N, Wilson AA, Meyer JH, Hussey D, et al. (2001). Positron emission tomography quantification of 11C-DASB binding to the human serotonin transporter: modeling strategies. Journal of Cerebral Blood Flow and Metabolism 21, 1342-1353.
8. Halldin C, Lundberg J, So'va'gó J, Gulya's B, et al. (2005). 11CMADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse 58, 173-183.
9. Hesse S, Bartel H, Murai T, Muller U, et al. (2003). Is correction for age necessary in neuroimaging studies of the central serotonin transporter? European Journal of Nuclear Medicine and Molecular Imaging 30, 427-430.
10. Kuhn R (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry 115, 459-464.
11. L.D. Electronic Medicines Compendium (2010) Communications (http://www.medicines.org.uk). Accessed.
12. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. NeuroImage 4, 153-158.
13. Lundberg J, Borg J, Halldin C, Farde L (2007b). A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain. Psychopharmacology 195, 425-433.
14. Lundberg J, Halldin C, Farde L (2006). Measurement of serotonin transporter binding with PET and 11CMADAM: a test-retest reproducibility study. Synapse 60, 256-263.
15. Lundberg J, Odano I, Olsson H, Halldin C, et al. (2005). Quantification of 11C-MADAM binding to the serotonin transporter in the human brain. Journal of Nuclear Medicine 46, 1505-1515.
16. Lundberg J, Stroyer Christophersen JS, Buchberg Petersen K, Loft H, et al. (2007a). PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. International Journal of Neuropsychopharmacology 10, 777-785.
17. Meyer JH (2007). Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. Journal of Psychiatry and Neuroscience 32, 86-102.
18. Meyer JH, Wilson AA, Ginovart N, Goulding V, et al. (2001). Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a 11CDASB PET imaging study. American Journal of Psychiatry 158, 1843-1849.
19. Meyer JH, Wilson AA, Sagrati S, Hussey D, et al. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an 11CDASB positron emission tomography study. American Journal of Psychiatry 161, 826-835.
20. Montgomery SA, Rani J, McAuley R, Roy D, et al. (1980). The antidepressant efficacy of zimelidine and maprotiline. Acta Psychiatrica Scandinavica 290, 219-224.
21. Ross SB, Renyi AL (1969). Inhibition of the uptake of tritiated 5-hydroxytryptamine in brain tissue. European Journal of Pharmacology 7, 270-277.
22. Sekine M, Arakawa R, Ito H, Okumura M, et al. (2010). Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-18FFMeNER-D2. Psychopharmacology 210, 331-336.
23. Suhara T, Takano A, Sudo Y, Ichimiya T, et al. (2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Archives of General Psychiatry 60, 386-391.
24. Takano A, Nag S, Gulyas B, Halldin C, et al. (2011). NET occupancy by clomipramine and its active metabolite, desmethylclomipramine, in non-human primates in vivo. Psychopharmacology 216, 279-286.
25. Tarkiainen J, Vercouillie J, Emond P, Sandell J, et al. (2001). Carbon-11 labelling of MADAM in two different positions: a highly selective PET radioligand for the serotonin transporter. Journal of Labelled Compounds and Radiopharmaceuticals 44, 1013-1023.